Amgen Inc. · AMGN · Next earnings

Amgen Inc. reports Tuesday, Feb 2, 2027

AMGN reports after market close with consensus EPS at $5.73 and revenue at $10.44B. Last quarter: Amgen Q3: Growth Drivers, Pipeline Progress and Higher 2026 Guidance

Reports After market close89 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $5.73 Calendar consensus
Consensus revenue $10.44B Calendar consensus
Report date Feb 2, 2027 Tuesday, date estimated
Session After market close 89 days away

Where AMGN left off: FY2026 Q3

Full report

Amgen Q3: Growth Drivers, Pipeline Progress and Higher 2026 Guidance

EPS surprise +11.4% Reported $6.45 vs $5.79
Revenue surprise +3.0% Reported $10.37B vs $10.07B
Stock move +1.6% Event window
Subsequent drift 0.0% Up to 20 sessions

Management raised 2026 revenue and EPS guidance again, according to the supplied Q3 analysis. Exact updated ranges were not provided in the analysis.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Regulatory timing and clinical outcomes for late-stage programs, including dazodalibep and MariTide.
  • Competitive pressure and uncertain pricing, reimbursement and adoption in biosimilars, oncology and obesity therapies.
  • Manufacturing capacity and launch execution as the pipeline and product portfolio expand.

Questions analysts left open

  • Regulatory pathway and timing for dazodalibep in symptomatic Sjögren’s disease.
  • MariTide’s Phase III safety and tolerability data, and whether biosimilar capacity may be reassigned to support its launch.
  • IMDELLTRA adoption and monitoring logistics in first-line settings, along with the addressable market and reimbursement outlook.

Ask FN2 about AMGN next report

Transcript, numbers and history already loaded
What should I watch for in AMGN's next earnings report?How did AMGN guide last quarter, and is consensus above or below that?Give me the bull and bear case going into AMGN earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the AMGN recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent AMGN quarters

All AMGN earnings
+1.6%FY2026 Q3+4.6%FY2026 Q2-4.7%FY2026 Q1+7.8%FY2025 Q3

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q3

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.